[go: up one dir, main page]

EA201690044A1 - Модуляторы ядерного транспорта и их применение - Google Patents

Модуляторы ядерного транспорта и их применение

Info

Publication number
EA201690044A1
EA201690044A1 EA201690044A EA201690044A EA201690044A1 EA 201690044 A1 EA201690044 A1 EA 201690044A1 EA 201690044 A EA201690044 A EA 201690044A EA 201690044 A EA201690044 A EA 201690044A EA 201690044 A1 EA201690044 A1 EA 201690044A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
nuclear transport
transport modulators
compounds
formula
Prior art date
Application number
EA201690044A
Other languages
English (en)
Other versions
EA029743B1 (ru
Inventor
Эркан Балоглу
Шэрон Шачам
Дилара Макколи
Тринаян Кашьяп
Уильям Сенапедис
Йосеф Ландесман
Гали Голан
Ори Калид
Шарон Шечтер
Original Assignee
Кариофарм Терапевтикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кариофарм Терапевтикс, Инк. filed Critical Кариофарм Терапевтикс, Инк.
Publication of EA201690044A1 publication Critical patent/EA201690044A1/ru
Publication of EA029743B1 publication Critical patent/EA029743B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)и их фармацевтически приемлемым солям, фармацевтическим композициям, содержащим соединения формулы (I) или их фармацевтически приемлемые соли, и способам применения указанных соединений, солей и композиций в лечении разных нарушений, ассоциированных с активностью CRM1.
EA201690044A 2013-06-21 2014-06-20 Модуляторы ядерного транспорта и их применение EA029743B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838172P 2013-06-21 2013-06-21
PCT/US2014/043479 WO2014205389A1 (en) 2013-06-21 2014-06-20 Nuclear transport modulators and uses thereof

Publications (2)

Publication Number Publication Date
EA201690044A1 true EA201690044A1 (ru) 2016-05-31
EA029743B1 EA029743B1 (ru) 2018-05-31

Family

ID=51177201

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690044A EA029743B1 (ru) 2013-06-21 2014-06-20 Модуляторы ядерного транспорта и их применение

Country Status (28)

Country Link
US (5) US9738624B2 (ru)
EP (2) EP3010892B8 (ru)
JP (2) JP6730922B2 (ru)
KR (2) KR102322794B1 (ru)
CN (3) CN110183422B (ru)
AU (5) AU2014284168B2 (ru)
BR (1) BR112015032071B1 (ru)
CA (1) CA2915365C (ru)
CY (1) CY1122730T1 (ru)
DK (2) DK3010892T3 (ru)
EA (1) EA029743B1 (ru)
ES (2) ES2952774T3 (ru)
HR (1) HRP20190524T1 (ru)
HU (1) HUE042800T2 (ru)
IL (2) IL243099B (ru)
LT (1) LT3010892T (ru)
ME (1) ME03421B (ru)
MX (1) MX365939B (ru)
PL (1) PL3010892T3 (ru)
PT (1) PT3010892T (ru)
RS (1) RS58581B1 (ru)
SG (1) SG11201510036TA (ru)
SI (1) SI3010892T1 (ru)
SM (1) SMT201900184T1 (ru)
TR (1) TR201904455T4 (ru)
UA (1) UA119238C2 (ru)
WO (1) WO2014205389A1 (ru)
ZA (1) ZA201509015B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
LT2736887T (lt) 2011-07-29 2018-02-12 Karyopharm Therapeutics, Inc. Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
HUE050452T2 (hu) 2012-05-09 2021-03-29 Biogen Ma Inc Nukleáris transzport modulátorok és alkalmazásuk
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
EP3180331B1 (en) 2014-08-15 2022-06-08 Karyopharm Therapeutics Inc. Polymorphs of selinexor
EP3397634A1 (en) * 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117529A1 (en) * 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11065230B2 (en) * 2016-09-16 2021-07-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
CN111836798B (zh) 2018-01-10 2022-04-15 凯瑞康宁生物工程（武汉）有限公司 氯胺酮的前药、其组合物和用途
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
US12318386B2 (en) * 2018-09-07 2025-06-03 Karyopharm Therapeutics Inc. Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
JP2022510736A (ja) 2018-12-05 2022-01-27 株式会社スコヒアファーマ 大環状化合物とその使用
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
WO2021202745A1 (en) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Treatment of covid-19 with a sine compound
CN113880803B (zh) * 2020-07-03 2024-07-02 上海天慈国际药业有限公司 一种xpo-1抑制剂的制备方法
WO2022089629A1 (zh) * 2020-11-02 2022-05-05 江苏柯菲平医药股份有限公司 1,2,4-三氮唑衍生物及其制备方法和用途
CN112294819B (zh) * 2020-12-03 2021-12-14 中国人民解放军军事科学院军事医学研究院 一种炎症小体抑制剂及其应用
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
US20240287041A1 (en) 2021-05-20 2024-08-29 Karyopharm Therapeutics Inc. Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
CN113248474A (zh) * 2021-05-24 2021-08-13 王能能 五元氮唑杂环衍生物及其制备方法和用途
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
CN117940409A (zh) * 2021-09-08 2024-04-26 南京明德新药研发有限公司 丙烯酰胺类化合物及其应用
MX2024004871A (es) * 2021-10-29 2024-05-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto que contiene piridilo.
WO2023134629A1 (zh) * 2022-01-12 2023-07-20 上海海雁医药科技有限公司 核转运调节剂及其用途
WO2024102477A1 (en) 2022-11-11 2024-05-16 Karyopharm Therapeutics Inc. Crystalline forms of eltanexor and process for preparing same
TWI863768B (zh) * 2023-12-21 2024-11-21 友達光電股份有限公司 顯示裝置

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
JP2941950B2 (ja) 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (de) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
KR20000005238A (ko) 1996-04-04 2000-01-25 시오노 요시히코 세펨 화합물 및 그 화합물을 함유하는 약제
AU736854B2 (en) 1996-04-25 2001-08-02 Nissan Chemical Industries Ltd. Ethylene derivatives and pesticides containing said derivatives
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (fr) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
CA2566094A1 (en) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
EP1780210A4 (en) 2004-08-11 2009-06-10 Kyorin Seiyaku Kk NEW CYCLIC DERIVATIVE OF AMINOBENZOIC ACID
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006088246A1 (ja) 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
CN101309912B (zh) 2005-11-15 2013-09-25 大塚制药株式会社 噁唑化合物和药物组合物
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
HRP20120174T1 (hr) 2006-03-09 2012-03-31 Eisai R&D Management Co. Derivat policikličnog cinamida
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
CN102643248A (zh) 2006-04-18 2012-08-22 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
JP5254228B2 (ja) 2006-07-27 2013-08-07 株式會社アモーレパシフィック バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20110009374A1 (en) 2009-07-09 2011-01-13 Keller Brian C Method of wound healing and scar modulation
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
AU2012207565B2 (en) * 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
LT2736887T (lt) 2011-07-29 2018-02-12 Karyopharm Therapeutics, Inc. Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
HUE050452T2 (hu) 2012-05-09 2021-03-29 Biogen Ma Inc Nukleáris transzport modulátorok és alkalmazásuk
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015073908A1 (en) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
EP3180331B1 (en) 2014-08-15 2022-06-08 Karyopharm Therapeutics Inc. Polymorphs of selinexor
WO2017117529A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
US10993943B2 (en) 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
GB2591846B (en) 2019-12-06 2024-08-14 Bae Systems Plc Light source
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
US20160152596A1 (en) 2016-06-02
AU2024204818A1 (en) 2024-08-01
ZA201509015B (en) 2018-07-25
CN110386919A (zh) 2019-10-29
AU2014284168B2 (en) 2018-10-25
RS58581B1 (sr) 2019-05-31
BR112015032071A2 (pt) 2017-07-25
ES2952774T3 (es) 2023-11-06
EP3010892B8 (en) 2019-05-22
PL3010892T3 (pl) 2019-07-31
KR102545732B1 (ko) 2023-06-20
US9738624B2 (en) 2017-08-22
ES2724275T3 (es) 2019-09-09
EP3492455B1 (en) 2023-05-17
SMT201900184T1 (it) 2019-05-10
DK3492455T3 (da) 2023-08-14
CA2915365A1 (en) 2014-12-24
US20250059158A1 (en) 2025-02-20
DK3010892T3 (en) 2019-04-15
US20220177445A1 (en) 2022-06-09
KR20160029076A (ko) 2016-03-14
EP3010892B1 (en) 2018-12-26
UA119238C2 (uk) 2019-05-27
AU2020277088A1 (en) 2020-12-24
LT3010892T (lt) 2019-04-10
AU2020277088B2 (en) 2022-09-08
JP2020172527A (ja) 2020-10-22
CN105339358B (zh) 2019-06-04
CN110386919B (zh) 2023-07-14
CN110183422B (zh) 2023-07-14
EP3010892A1 (en) 2016-04-27
WO2014205389A1 (en) 2014-12-24
EA029743B1 (ru) 2018-05-31
IL261612A (en) 2018-10-31
NZ714931A (en) 2021-02-26
SG11201510036TA (en) 2016-01-28
TR201904455T4 (tr) 2019-04-22
JP2016522266A (ja) 2016-07-28
US11124493B2 (en) 2021-09-21
AU2022283662A1 (en) 2023-02-02
MX2015016983A (es) 2016-07-21
AU2019200147A1 (en) 2019-01-31
HRP20190524T1 (hr) 2019-05-17
WO2014205389A8 (en) 2015-04-02
IL243099A0 (en) 2016-02-01
CN110183422A (zh) 2019-08-30
IL243099B (en) 2020-09-30
HUE042800T2 (hu) 2019-07-29
HK1223936A1 (en) 2017-08-11
PT3010892T (pt) 2019-04-12
MX365939B (es) 2019-06-19
KR102322794B1 (ko) 2021-11-05
CY1122730T1 (el) 2021-03-12
EP3492455A1 (en) 2019-06-05
JP6730922B2 (ja) 2020-07-29
US20180155317A1 (en) 2018-06-07
SI3010892T1 (sl) 2019-05-31
US10407405B2 (en) 2019-09-10
ME03421B (me) 2020-01-20
BR112015032071B1 (pt) 2022-06-14
AU2014284168A1 (en) 2015-12-24
US20200199099A1 (en) 2020-06-25
US11945794B2 (en) 2024-04-02
JP7061161B2 (ja) 2022-04-27
CN105339358A (zh) 2016-02-17
KR20210137223A (ko) 2021-11-17
CA2915365C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201590562A1 (ru) Бензамиды
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба